CharlesJoelRosserMDMBA
Urology • Los Angeles, CASurgical Oncology
Professor and Medical Director Cedars-Sinai CANCER Clinical Trials Office
Dr. Rosser is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
8700 Beverly Blvd
Los Angeles, CA 90048- Is this information wrong?
Summary
- Dr. Charles Rosser is an urologist in Los Angeles, CA and is affiliated with Cedars-Sinai Medical Center. He received his medical degree from Rutgers Robert Wood Johnson Medical School and has been in practice 23 years. He specializes in surgical oncology and is experienced in bladder tumors, clinical research, and turbt.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Urologic Surgical Oncology, 2000 - 2003
Wake Forest University School of MedicineResidency, Urology, 1994 - 2000
Rutgers Robert Wood Johnson Medical SchoolClass of 1994
Certifications & Licensure
HI State Medical License 2013 - 2024
CA State Medical License 2018 - 2024
FL State Medical License 2003 - 2023
NC State Medical License 2005 - 2017
TX State Medical License 2000 - 2017- American Board of Urology Urology
Clinical Trials
- Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer Start of enrollment: 2003 Nov 01
- A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Start of enrollment: 2011 Jun 01
- A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer Start of enrollment: 2012 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Assessing the Causal Relationship between Waterpipe Smoking and Bladder Cancer.Charles J Rosser> ;Cancer Epidemiology, Biomarkers & Prevention. 2024 Apr 3
- MRI/RNA-Seq-Based Radiogenomics and Artificial Intelligence for More Accurate Staging of Muscle-Invasive Bladder Cancer.Qureshi, T., Chen, X., Xie, Y., Murakami, K., Sakatani, T., Kita, Y., Kobayashi, T., Miyake, M., Knott, S., Li, D., Furuya, H., Rosser, C.> ;International Journal of Molecular Sciences. 2023 Dec 20
- Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Letter.Peris R Castaneda, Michael Ahdoot, Charles J Rosser> ;The Journal of Urology. 2023 Apr 1
- Join now to see all
Press Mentions
New Bladder Cancer Diagnostic Receives Approval for Sale in EuropeJune 22nd, 2022- Nonagen Bioscience Announces CE Mark for Oncuria® Bladder Cancer DiagnosticJune 16th, 2022
- Bio-Techne and Nonagen Bioscience Announce Exclusive Supply Agreement for Nonagen's Oncuria® Bladder Cancer TestMay 12th, 2022
- Join now to see all
Grant Support
- Multiplexed protein biomarker for the non-invasive detection of bladder cancerNCI2016–2021
Hospital Affiliations
Cedars-Sinai Medical CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
